comparemela.com
Home
Live Updates
Stephaniet Le - Breaking News
Pages:
Stephaniet Le News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Combined Rituximab + Omalizumab Promising for Refractory BP
Bullous pemphigoid has high morbidity and mortality, especially in people with comorbidities common to older adults, yet no Food and Drug Administration–approved therapies for BP exist.
United states
Stephaniet le
University of california
Drug administration
Corticosteroids are
Biologic therapy
Antineoplastic drug
Nti cancer agents
Monoclonal antibody
Bullous pemphigoid
Topical corticosteroid
Elder care
Geriatric medicine
Older adults
Senior citizens
Elderly concerns of older adults
Rituximab, Omalizumab Combination Therapy Well-Tolerated for Patients With Bullous Pemphigoid
This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment.
United states
Stephaniet le
University of california
Department of dermatology
Department of dermatology at university california
Pacific islander
Bullous pemphigoid
Rituximab, Omalizumab Combination Therapy Well-Tolerated for Bullous Pemphigoid Patients
This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment.
United states
Stephaniet le
Department of dermatology at university california
Department of dermatology
University of california
Drug administration
Pacific islander
Hispanic white
Omalizumab combination therapy
Bullous pemphigoid
vimarsana © 2020. All Rights Reserved.